Benzinga  Jul 27  Comment 
AstraZeneca (NYSE: AZN) today announced that it has entered into a definitive agreement with Genzyme (NYSE: SNY) to divest Caprelsa® (vandetanib), a rare disease medicine. Caprelsa was granted Orphan Drug Designation by the US FDA in 2005 and...
New York Times  Jul 25  Comment 
The drug, Praluent, developed by Sanofi and Regeneron, is expected to become the next flashpoint in the growing controversy of escalating pharmaceutical price.
New York Times  Jul 24  Comment 
The drug, Praluent, developed by Sanofi and Regeneron, is expected to become the next flashpoint in the growing controversy of escalating pharmaceutical price.
FiercePharma  Jul 22  Comment 
Sanofi's Genzyme is testing an oral drug for Fabry disease, which would go up against its own Fabrazyme if and when it wins approval. But the company knows a thing or two about bringing new pills to market while keeping sales of older drugs intact.
Forbes  Jul 21  Comment 
I’m a huge fan of R&D collaborations between pharma and academia, so I should be thrilled by Sanofi’s latest tie-up with seven top-tier centers – so why do I have mixed feelings?
The Hindu Business Line  Jul 21  Comment 
Drug firm Sanofi India today reported a 11.65 per cent rise in its standalone net profit at Rs 64.2 crore during second quarter ended June 30, 2015.The company, which follows January-Decembe...
FierceBiotech  Jul 21  Comment 
Amgen may be running a beat or two behind Regeneron and Sanofi in search of the first FDA approval for a PCSK9 drug, but the Big Biotech scooped up the very first approval in Europe today for Repatha (evolocumab), giving the company boasting...
FiercePharma  Jul 20  Comment 
With more than $1.5 billion in development costs and 20 years of research on the line, Sanofi is getting revved up to launch its world-first dengue vaccine later this year. And if the company's predictions are correct, the shot will not only be a...
FierceBiotech  Jul 16  Comment 
FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including Celgene's planned acquisition of Receptos, Sanofi's latest corporate restructuring and an alarming new ad from GlaxoSmithKline.


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki